These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15856433)

  • 1. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
    Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
    Miura M
    Yakugaku Zasshi; 2006 Jun; 126(6):395-402. PubMed ID: 16755125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
    Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
    Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
    J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
    Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
    Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
    Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
    Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
    Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
    Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
    Xenobiotica; 2006 Jan; 36(1):95-102. PubMed ID: 16507515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
    Miura M; Kagaya H; Tada H; Sagae Y; Satoh S; Habuchi T; Suzuki T
    Xenobiotica; 2005 May; 35(5):479-86. PubMed ID: 16012079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
    Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
    Niioka T; Miura M; Uno T; Yasui-Furukori N; Hayakari M; Tateishi T; Suzuki T
    Eur J Clin Pharmacol; 2008 May; 64(5):503-9. PubMed ID: 18224311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.